DCVC Bio

DCVC Bio

DCVC, the parent franchise, was founded in 2011 by Zachary Bogue and Matthew Ocko and manages roughly $4 billion across 13 funds, per its website. The firm carved out DCVC Bio in 2018 specifically to apply the Data Collective's computional ethos to therapeutics, agriculture, and industrial biotechnology. The dedicated bio team sits alongside six flagship deep tech funds but operates with its own investment committee and sectoral mandate. The bio arm runs three funds targeting computationally enabled life sciences. Its investment team integrates genetics, chemistry, molecular biology, and AI to back companies from preclinical through commercialization. Confirmed positions include Latus Bio, which engineers viral vectors for CNS disorders, and Pivot Bio, which reprograms soil microbes to replace synthetic nitrogen fertilizers. The franchise also lists Relation, a machine learning–driven drug discovery platform, and Kanvas, which attempts to make the microbiome druggable, though it is not specified whether these sit inside DCVC Bio or the general fund portfolio. Geographic focus spans the United States, with no non-US offices flagged. Total DCVC has 45 team members across the franchise, with a bio-specific group that includes Managing Partners Hamer and Stead, Partner Dr. Justin Kern, Principal Dr. Emily Park, Operating Partners Dr. Andy May and Serge Messerlian, and Entrepreneurs in Residence Dr. Adil Anjem and Christopher Meldrum. No discrete AUM figure for DCVC Bio is disclosed. In May 2026, parent-company portfolio firm Fervo Energy completed an IPO, though the fund assignment is not specified. A structural differentiator is the franchise's decision to house bio inside a multi-fund deep tech complex rather than spinning it out. This gives DCVC Bio operating partners who have built supercomputer racks and read chip architecture, alongside clinicians, creating a crossover sourcing model where expertise in exa-scale computing and materials science can leak into drug and ag-bio discovery. The firm explicitly notes it employs more published scientists than MBAs.